TY - JOUR
T1 - Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database
AU - Noda, Aoi
AU - Sakai, Takamasa
AU - Obara, Taku
AU - Miyazaki, Makoto
AU - Tsuchiya, Masami
AU - Oyanagi, Gen
AU - Murai, Yuriko
AU - Mano, Nariyasu
N1 - Funding Information:
The design of the study was supported by the grant from the Ministry of Health, Labour and Welfare of Japan (H24-iyakuwakate-011). The interpretation of data, analysis, and writing the manuscript were supported by the grants from Research on Regulatory Harmonization and Evaluation of Pharmaceuticals, Medical Devices, Regenerative and Cellular Therapy Products, Gene Therapy Products, and Cosmetics from the Japan Agency for Medical Research and Development, AMED (17mk0101095h0001, 18mk0101095h0002) and the Japan Society for the Promotion of Science (JSPS) (19 K07213).
Publisher Copyright:
© 2020 The Author(s).
PY - 2020/5/24
Y1 - 2020/5/24
N2 - Background: There are no reports on investigations of the characteristics of adverse drug reaction (ADR) reports for pediatric patients in the Japanese Adverse Drug Event Report database (JADER) and the utility of database for drug safety surveillance in these patients. Method: We aimed to evaluate ADR reports for pediatric patients in the JADER. We used spontaneous ADR reports included in the JADER since April 1, 2004, to December 31, 2017, which was downloaded in April 2018. In a total of 504,407 ADR reports, the number of spontaneous reports was 386,400 (76.6%), in which 37,534 (7.4%) were unknown age reports. After extraction of 27,800 ADR reports for children aged < 10 and 10-19 years, we excepted for ADR reports associated with a vaccine (n = 6355) and no-suspected drug reports (n = 86). A total of 21,359 (4.2%) reports were finally included in this analysis. Results: More than half of the ADR reports were for children aged < 10 years. Approximately 30% of ADR reports had multiple suspected drugs, which did not differ by age. The percentages of fatal outcomes of ADRs among patients aged < 10 and 10-19 years were 4.7 and 3.9%, respectively. The most frequently reported drug, reaction, and drug-reaction pair were oseltamivir, abnormal behavior, and oseltamivir and abnormal behavior, respectively. Conclusion: We clarified the characteristics of ADR reports for Japanese children by using the JADER. ADR report databases, especially those for pediatric patients, are valuable pharmacovigilance tools in Japan and other countries. Therefore, a proper understanding of the characteristics of the ADR reports in the JADER is important. Additionally, potential signals for ADRs in pediatric patients should be monitored continuously and carefully.
AB - Background: There are no reports on investigations of the characteristics of adverse drug reaction (ADR) reports for pediatric patients in the Japanese Adverse Drug Event Report database (JADER) and the utility of database for drug safety surveillance in these patients. Method: We aimed to evaluate ADR reports for pediatric patients in the JADER. We used spontaneous ADR reports included in the JADER since April 1, 2004, to December 31, 2017, which was downloaded in April 2018. In a total of 504,407 ADR reports, the number of spontaneous reports was 386,400 (76.6%), in which 37,534 (7.4%) were unknown age reports. After extraction of 27,800 ADR reports for children aged < 10 and 10-19 years, we excepted for ADR reports associated with a vaccine (n = 6355) and no-suspected drug reports (n = 86). A total of 21,359 (4.2%) reports were finally included in this analysis. Results: More than half of the ADR reports were for children aged < 10 years. Approximately 30% of ADR reports had multiple suspected drugs, which did not differ by age. The percentages of fatal outcomes of ADRs among patients aged < 10 and 10-19 years were 4.7 and 3.9%, respectively. The most frequently reported drug, reaction, and drug-reaction pair were oseltamivir, abnormal behavior, and oseltamivir and abnormal behavior, respectively. Conclusion: We clarified the characteristics of ADR reports for Japanese children by using the JADER. ADR report databases, especially those for pediatric patients, are valuable pharmacovigilance tools in Japan and other countries. Therefore, a proper understanding of the characteristics of the ADR reports in the JADER is important. Additionally, potential signals for ADRs in pediatric patients should be monitored continuously and carefully.
KW - Adverse drug reaction
KW - Children
KW - Drug safety
KW - Pediatric patients
KW - Pharmacovigilance
KW - Signal detection
KW - Spontaneous reports
KW - The JADER
UR - http://www.scopus.com/inward/record.url?scp=85085447142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085447142&partnerID=8YFLogxK
U2 - 10.1186/s40360-020-00412-7
DO - 10.1186/s40360-020-00412-7
M3 - Article
C2 - 32448369
AN - SCOPUS:85085447142
VL - 21
JO - BMC pharmacology & toxicology
JF - BMC pharmacology & toxicology
SN - 2050-6511
IS - 1
M1 - 36
ER -